Combination Product: AURN001 + Y-27632

Phase 3Small molecule

Combination Product: AURN001 + Y-27632 is one of 42 small molecule programs targeting Endothelial Dysfunction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Endothelial DysfunctionPhase 3

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Endothelial Dysfunction

#DrugCompanyPhaseTrials

Avapro

Sanofi

Approved

2 2

Uloric

Takeda

Phase 3

2 3

Diamicron

Merck & Co.

Phase 3

1 4

Inomax

MMallinckrodt

Phase 3

1 5

Januvia

ZZydus Therapeutics Inc.

Phase 3

1 6

Glucophage

EMD Serono

Phase 3

1 7

Kremezin

Astellas

Approved

1 8

Kuvan

BioMarin Pharmaceutical

Phase 2

1 9

Viagra

VViatris Specialty LLC

Phase 2

1 10

Aurlumyn

BBTG International Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Endothelial Dysfunction

NCT07368959

Clinical

Trials by Indication[1]

Endothelial Dysfunction1 trial

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Recruiting·AAurion Biotech·Phase 3·NCT07368959·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combination Product: AURN001 + Y-27632. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination Product: AURN001 + Y-27632 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination Product: AURN001 + Y-27632. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aurion Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAurion Biotech

Combination Product: AURN001 + Y-27632

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Endothelial Dysfunction1 trial

References

Drug Info

Quick Facts

Related News